Asia Pacific Point of Care TB And Drug-resistant TB Testing Market To Reach $4.0 Billion By 2030

Asia Pacific Point of Care TB And Drug-resistant TB Testing Market Growth & Trends

The Asia Pacific point of care TB and drug-resistant TB testing market size is anticipated to reach USD 4.0 billion by 2030 and is projected to grow at a CAGR of 6.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of tuberculosis (TB) in the region is primarily driving market’s growth. Countries like India, China, Indonesia, and the Philippines contribute significantly to the global TB burden. For instance, India alone accounted for about 27.0% of the world's TB cases in 2022, according to the World Health Organization (WHO). This high incidence necessitates efficient diagnostic solutions to manage and control TB, including drug-resistant forms.

Recent technological advancements are also fueling market growth. Innovations such as rapid molecular diagnostic tests, including the GeneXpert MTB/RIF assay, significantly improve diagnostic speed and accuracy. These technologies enable fast detection of TB and drug resistance, providing results in hours rather than days or weeks. Such advancements are crucial in high-burden areas where timely diagnosis is essential to prevent the spread of disease and improve patient outcomes. Integrating digital health solutions and automated testing systems further enhances diagnostic capabilities, supporting market expansion.

Government initiatives and regulatory support play a substantial role in driving market growth. Governments across the Asia Pacific are investing in TB control programs and diagnostic infrastructure to combat the high TB burden. For example, India's National Strategic Plan for Tuberculosis Elimination 2017-2025 emphasizes enhancing diagnostic services. Similarly, international organizations such as the Global Fund provide financial and technical assistance to improve diagnostic and treatment capabilities. These efforts and streamlined regulatory processes that facilitate the approval & adoption of new diagnostic technologies are crucial in supporting the market's growth and ensuring effective TB management in the region. 

 Request a free sample copy or view report summary: Asia Pacific Point of Care TB And Drug-resistant TB Testing Market Report

Asia Pacific Point of Care TB And Drug-resistant TB Testing Market Report Highlights

• Based on test, the immunoassays segment dominated the market with a substantial revenue share of 34.6% in 2023. This prominence can be attributed to the technology's established efficacy, ease of use, and adaptability in diverse settings.

• Based on end use, the clinics and hospitals segment dominated the market with the largest revenue share of 48.0% in 2023. This prominence is primarily driven by the critical role these healthcare settings play in comprehensive patient management, advancements in diagnostic technologies, and the escalating need for effective TB and drug-resistant TB diagnostics.

• In July 2023, EMPE Diagnostics launched the mfloDx MDR-TB rapid test kit, a precise, quick, and inexpensive test that provides accurate information on Mycobacterium tuberculosis presence and genotypic resistance. It was approved by the CDSCO and is currently undergoing clinical testing in other nations.

• Several manufacturers are actively involved in Mergers and acquisitions (M&A) activities in this regional market, showcasing dynamic growth and consolidation

Asia Pacific Point of Care TB And Drug-resistant TB Testing Market Segmentation

Grand View Research has segmented the Asia Pacific PoC TB and drug-resistant TB testing market based on test, end use, and country:

Asia Pacific PoC TB & Drug-resistant TB Testing Test Outlook (Revenue, USD Million, 2018 - 2030)

• Molecular Diagnostics

• Immunoassays

• Culture-based Tests

• Serological Tests

• Others

Asia Pacific PoC TB & Drug-resistant TB Testing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Clinics & Hospitals

• Diagnostic Laboratories

• Others

Asia Pacific PoC TB & Drug-resistant TB Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Southeast Asia

  • Rest of APAC

Key Players in Asia Pacific Point of Care (PoC) TB And Drug-resistant TB Testing Market 

• Cepheid (Danaher Corporation)

• Molbio Diagnostics

• Abbott Laboratories

• BD (Becton, Dickinson and Company)

• Roche Diagnostics

• Qiagen

• Lucira Health

• BioMérieux

• Thermo Fisher Scientific

• Fujifilm (Fujifilm Healthcare)

• MedMira

• SD Biosensor

• Trivitron Healthcare